딜티아젬 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "딜티아젬" in Korean language version.

refsWebsite

Global rank Korean rank

16nih.gov

4^th place

13doi.org

2^nd place

3^rd place

7semanticscholar.org

11^th place

310^th place

4archive.org

6^th place

18^th place

3web.archive.org

1^st place

2drugs.com

399^th place

141^st place

2medicines.org.uk

3,823^rd place

2,321^st place

2books.google.com

3^rd place

9^th place

2clincalc.com

3,912^th place

2,490^th place

1europa.eu

68^th place

145^th place

1health.kr

low place

2,285^th place

1pharmaceutical-journal.com

low place

archive.org

《2010 Nurse's Drug Handbook》. Jones & Bartlett Learning. 2010. 320쪽. ISBN 978-0-7637-7900-9.
Gabrielli A, Gallagher TJ, Caruso LJ, Bennett NT, Layon AJ (October 2001). “Diltiazem to treat sinus tachycardia in critically ill patients: a four-year experience”. 《Critical Care Medicine》 29 (10): 1874–1879. doi:10.1097/00003246-200110000-00004. PMID 11588443. S2CID 25104288.
Wattanasuwan N, Khan IA, Mehta NJ, Arora P, Singh N, Vasavada BC, Sacchi TJ (February 2001). “Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone”. 《Chest》 119 (2): 502–506. doi:10.1378/chest.119.2.502. PMID 11171729.
Gordon SG, Kittleson MD (2008). 〈Drugs used in the management of heart disease and cardiac arrhythmias〉. 《Small Animal Clinical Pharmacology》. Elsevier. 380–457쪽. doi:10.1016/b978-070202858-8.50019-1. ISBN 978-0-7020-2858-8.

books.google.com

《Cardiovascular Pharmacotherapeutics》. Cardiotext Publishing. 2011. 251–52쪽. ISBN 978-1-935395-62-1. 2018년 12월 28일에 확인함.
Milne GW (2005). 《Gardner's Commercially Important Chemicals: Synonyms, Trade Names, and Properties》. John Wiley & Sons. 223쪽. ISBN 978-0-471-73661-5. 2018년 12월 28일에 확인함.

clincalc.com

“The Top 300 of 2021”. 《ClinCalc》. 2024년 1월 15일에 원본 문서에서 보존된 문서. 2024년 1월 14일에 확인함.
“Diltiazem - Drug Usage Statistics”. 《ClinCalc》. 2024년 1월 14일에 확인함.

doi.org

dx.doi.org

Grossman E, Messerli FH (2004). “Calcium antagonists”. 《Progress in Cardiovascular Diseases》 47 (1): 34–57. doi:10.1016/j.pcad.2004.04.006. PMID 15517514.
Claas SA, Glasser SP (May 2005). “Long-acting diltiazem HCl for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris”. 《Expert Opinion on Pharmacotherapy》 6 (5): 765–776. doi:10.1517/14656566.6.5.765. PMID 15934903. S2CID 39272285.
Gabrielli A, Gallagher TJ, Caruso LJ, Bennett NT, Layon AJ (October 2001). “Diltiazem to treat sinus tachycardia in critically ill patients: a four-year experience”. 《Critical Care Medicine》 29 (10): 1874–1879. doi:10.1097/00003246-200110000-00004. PMID 11588443. S2CID 25104288.
Wattanasuwan N, Khan IA, Mehta NJ, Arora P, Singh N, Vasavada BC, Sacchi TJ (February 2001). “Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone”. 《Chest》 119 (2): 502–506. doi:10.1378/chest.119.2.502. PMID 11171729.
Basile J (November 2004). “The role of existing and newer calcium channel blockers in the treatment of hypertension”. 《Journal of Clinical Hypertension》 6 (11): 621–629; quiz 630–631. doi:10.1111/j.1524-6175.2004.03683.x. PMC 8109670. PMID 15538095. S2CID 23440538.
Griffin N, Acheson AG, Jonas M, Scholefield JH (October 2002). “The role of topical diltiazem in the treatment of chronic anal fissures that have failed glyceryl trinitrate therapy”. 《Colorectal Disease》 4 (6): 430–435. doi:10.1046/j.1463-1318.2002.00376.x. PMID 12790914. S2CID 32959944.
Ramoska EA, Spiller HA, Winter M, Borys D (February 1993). “A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment”. 《Annals of Emergency Medicine》 22 (2): 196–200. doi:10.1016/S0196-0644(05)80202-1. PMID 8427431.
Ohno Y, Hisaka A, Suzuki H (2007). “General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs”. 《Clinical Pharmacokinetics》 46 (8): 681–696. doi:10.2165/00003088-200746080-00005. PMID 17655375. S2CID 41343222.
Edoute Y, Nagachandran P, Svirski B, Ben-Ami H (April 2000). “Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents”. 《Journal of Cardiovascular Pharmacology》 35 (4): 556–559. doi:10.1097/00005344-200004000-00007. PMID 10774785.
Narimatsu A, Taira N (August 1976). “Effects of atrio-ventricular conduction of calcium-antagonistic coronary vasodilators, local anaesthetics and quinidine injected into the posterior and the anterior septal artery of the atrio-ventricular node preparation of the dog”. 《Naunyn-Schmiedeberg's Archives of Pharmacology》 294 (2): 169–177. doi:10.1007/bf00507850. PMID 1012337. S2CID 21986119.
Matsumae H, Akatsuka H, Shibatani T (2010). 〈Diltiazem Synthesis〉. 《Encyclopedia of Industrial Biotechnology》. 1–20쪽. doi:10.1002/9780470054581.eib603. ISBN 978-0-471-79930-6.
O'Connor SE, Grosset A, Janiak P (1999). “The pharmacological basis and pathophysiological significance of the heart rate-lowering property of diltiazem”. 《Fundamental & Clinical Pharmacology》 13 (2): 145–153. doi:10.1111/j.1472-8206.1999.tb00333.x. PMID 10226758. S2CID 20440286.
Gordon SG, Kittleson MD (2008). 〈Drugs used in the management of heart disease and cardiac arrhythmias〉. 《Small Animal Clinical Pharmacology》. Elsevier. 380–457쪽. doi:10.1016/b978-070202858-8.50019-1. ISBN 978-0-7020-2858-8.

drugs.com

“Diltiazem Use During Pregnancy”. 《Drugs.com》. 2020년 5월 4일. 2020년 5월 5일에 확인함.
“Diltiazem Hydrochloride Monograph for Professionals”. 《Drugs.com》. AHFS. 2018년 12월 28일에 확인함.

europa.eu

ema.europa.eu

“Active substance(s): diltiazem” (PDF). European Medicines Agency. 2018년 1월 11일.

health.kr

“헤르벤주50mg”. 《약학정보원》. 2024년 5월 15일에 확인함.

medicines.org.uk

“Dilcardia SR 120 mg Prolonged-release hard capsules – Summary of Product Characteristics (SmPC)”. 《emc》. 2018년 3월 22일. 2021년 8월 28일에 원본 문서에서 보존된 문서. 2020년 4월 13일에 확인함.
“Angitil SR/XL Capsules – Summary of Product Characteristics (SmPC)”. 《(emc)》. 2019년 5월 7일. 2020년 4월 13일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Grossman E, Messerli FH (2004). “Calcium antagonists”. 《Progress in Cardiovascular Diseases》 47 (1): 34–57. doi:10.1016/j.pcad.2004.04.006. PMID 15517514.
Claas SA, Glasser SP (May 2005). “Long-acting diltiazem HCl for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris”. 《Expert Opinion on Pharmacotherapy》 6 (5): 765–776. doi:10.1517/14656566.6.5.765. PMID 15934903. S2CID 39272285.
Gabrielli A, Gallagher TJ, Caruso LJ, Bennett NT, Layon AJ (October 2001). “Diltiazem to treat sinus tachycardia in critically ill patients: a four-year experience”. 《Critical Care Medicine》 29 (10): 1874–1879. doi:10.1097/00003246-200110000-00004. PMID 11588443. S2CID 25104288.
Wattanasuwan N, Khan IA, Mehta NJ, Arora P, Singh N, Vasavada BC, Sacchi TJ (February 2001). “Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone”. 《Chest》 119 (2): 502–506. doi:10.1378/chest.119.2.502. PMID 11171729.
Basile J (November 2004). “The role of existing and newer calcium channel blockers in the treatment of hypertension”. 《Journal of Clinical Hypertension》 6 (11): 621–629; quiz 630–631. doi:10.1111/j.1524-6175.2004.03683.x. PMC 8109670. PMID 15538095. S2CID 23440538.
Griffin N, Acheson AG, Jonas M, Scholefield JH (October 2002). “The role of topical diltiazem in the treatment of chronic anal fissures that have failed glyceryl trinitrate therapy”. 《Colorectal Disease》 4 (6): 430–435. doi:10.1046/j.1463-1318.2002.00376.x. PMID 12790914. S2CID 32959944.
Ramoska EA, Spiller HA, Winter M, Borys D (February 1993). “A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment”. 《Annals of Emergency Medicine》 22 (2): 196–200. doi:10.1016/S0196-0644(05)80202-1. PMID 8427431.
Talreja O, Cassagnol M (2019). 〈Diltiazem〉. 《StatPearls》. Treasure Island (FL): StatPearls Publishing. PMID 30422532.
Ohno Y, Hisaka A, Suzuki H (2007). “General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs”. 《Clinical Pharmacokinetics》 46 (8): 681–696. doi:10.2165/00003088-200746080-00005. PMID 17655375. S2CID 41343222.
Edoute Y, Nagachandran P, Svirski B, Ben-Ami H (April 2000). “Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents”. 《Journal of Cardiovascular Pharmacology》 35 (4): 556–559. doi:10.1097/00005344-200004000-00007. PMID 10774785.
Narimatsu A, Taira N (August 1976). “Effects of atrio-ventricular conduction of calcium-antagonistic coronary vasodilators, local anaesthetics and quinidine injected into the posterior and the anterior septal artery of the atrio-ventricular node preparation of the dog”. 《Naunyn-Schmiedeberg's Archives of Pharmacology》 294 (2): 169–177. doi:10.1007/bf00507850. PMID 1012337. S2CID 21986119.
O'Connor SE, Grosset A, Janiak P (1999). “The pharmacological basis and pathophysiological significance of the heart rate-lowering property of diltiazem”. 《Fundamental & Clinical Pharmacology》 13 (2): 145–153. doi:10.1111/j.1472-8206.1999.tb00333.x. PMID 10226758. S2CID 20440286.

dailymed.nlm.nih.gov

“Cardizem- diltiazem hydrochloride tablet, coated”. 《DailyMed》. 2020년 6월 2일. 2022년 10월 23일에 확인함.
“Cardizem CD- diltiazem hydrochloride capsule, coated, extended release”. 《DailyMed》. 2020년 4월 30일. 2022년 10월 23일에 확인함.
“Cardizem LA- diltiazem hydrochloride tablet, extended release”. 《DailyMed》. 2019년 5월 2일. 2022년 10월 23일에 확인함.
“Diltiazem hydrochloride – diltiazem hydrochloride extended-release tablets tablet, extended release”. 《DailyMed》. 2019년 4월 1일. 2020년 4월 13일에 확인함.

pharmaceutical-journal.com

“Drug interactions: Interactions between fentanyl and drugs that inhibit CYP3A4”. 2017년 12월 3일에 원본 문서에서 보존된 문서. 2019년 6월 26일에 확인함.

semanticscholar.org

api.semanticscholar.org

Claas SA, Glasser SP (May 2005). “Long-acting diltiazem HCl for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris”. 《Expert Opinion on Pharmacotherapy》 6 (5): 765–776. doi:10.1517/14656566.6.5.765. PMID 15934903. S2CID 39272285.
Gabrielli A, Gallagher TJ, Caruso LJ, Bennett NT, Layon AJ (October 2001). “Diltiazem to treat sinus tachycardia in critically ill patients: a four-year experience”. 《Critical Care Medicine》 29 (10): 1874–1879. doi:10.1097/00003246-200110000-00004. PMID 11588443. S2CID 25104288.
Basile J (November 2004). “The role of existing and newer calcium channel blockers in the treatment of hypertension”. 《Journal of Clinical Hypertension》 6 (11): 621–629; quiz 630–631. doi:10.1111/j.1524-6175.2004.03683.x. PMC 8109670. PMID 15538095. S2CID 23440538.
Griffin N, Acheson AG, Jonas M, Scholefield JH (October 2002). “The role of topical diltiazem in the treatment of chronic anal fissures that have failed glyceryl trinitrate therapy”. 《Colorectal Disease》 4 (6): 430–435. doi:10.1046/j.1463-1318.2002.00376.x. PMID 12790914. S2CID 32959944.
Ohno Y, Hisaka A, Suzuki H (2007). “General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs”. 《Clinical Pharmacokinetics》 46 (8): 681–696. doi:10.2165/00003088-200746080-00005. PMID 17655375. S2CID 41343222.
Narimatsu A, Taira N (August 1976). “Effects of atrio-ventricular conduction of calcium-antagonistic coronary vasodilators, local anaesthetics and quinidine injected into the posterior and the anterior septal artery of the atrio-ventricular node preparation of the dog”. 《Naunyn-Schmiedeberg's Archives of Pharmacology》 294 (2): 169–177. doi:10.1007/bf00507850. PMID 1012337. S2CID 21986119.
O'Connor SE, Grosset A, Janiak P (1999). “The pharmacological basis and pathophysiological significance of the heart rate-lowering property of diltiazem”. 《Fundamental & Clinical Pharmacology》 13 (2): 145–153. doi:10.1111/j.1472-8206.1999.tb00333.x. PMID 10226758. S2CID 20440286.

web.archive.org

“Dilcardia SR 120 mg Prolonged-release hard capsules – Summary of Product Characteristics (SmPC)”. 《emc》. 2018년 3월 22일. 2021년 8월 28일에 원본 문서에서 보존된 문서. 2020년 4월 13일에 확인함.
“The Top 300 of 2021”. 《ClinCalc》. 2024년 1월 15일에 원본 문서에서 보존된 문서. 2024년 1월 14일에 확인함.
“Drug interactions: Interactions between fentanyl and drugs that inhibit CYP3A4”. 2017년 12월 3일에 원본 문서에서 보존된 문서. 2019년 6월 26일에 확인함.